9 assets in Salivary Gland Cancer

Therapeutic assets addressing Salivary Gland Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Salivary Gland Cancer	OncoC4, Inc.	P2	B (60)
Entrectinib Salivary Gland Cancer	Hoffmann-La Roche	P2	CCC (53)
Zanidatamab Salivary Gland Cancer	Jazz Pharmaceuticals	P2	CCC (53)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Salivary Gland Cancer	VM Oncology, LLC	P1/2	CCC (48)
Docetaxel Salivary Gland Cancer	National Cancer Institute (NCI)	P1/2	CC (47)
Gotistobart Salivary Gland Cancer	OncoC4, Inc.	P1/2	CC (47)
SX682 Salivary Gland Cancer	National Cancer Institute (NCI)	P1/2	CC (47)
Cadvec Salivary Gland Cancer	Baylor College of Medicine	P1	CC (43)